Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Redwire Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Redwire Corporation trades at $10.43 (market cap $2.03B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.2× Redwire Corporation's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| ACAD | RDW | |
|---|---|---|
Market Cap | $4.49B | $2.03B |
Sector | Health | Technology |
52-Week High | $28.06 | $25.90 |
52-Week Low | $20.06 | $5.06 |
Enterprise Value | $3.69B | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
RDW trades at $11.36, up 0.44% on the day, amid a bearish technical trend and weak fundamentals. The company reported a net loss of $226.55M in 2025 with a -80.9% net income margin, though revenue grew to $335.38M. Recent news highlights volatility driven by SpaceX's IPO impact and a new defense contract, while analyst consensus remains bullish with an $19.00 price target.
The outlook is challenged by persistent losses and cash burn, but strong analyst buy ratings and contract wins offer potential upside. Key risks include dilution from equity offerings, intense space sector competition, and reliance on financing to fund operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
